From Nasdaq.: 2025-05-19 22:02:00

XORTX Therapeutics Inc. has launched a private placement to raise up to $3 million by issuing 3,409,090 common share units at $0.88 per unit. Each unit includes one common share and one purchase warrant, which allows the holder to buy an additional share at $1.20 within 60 months. XORTX may pay finder’s fees and all securities will be under a holding period. The company plans to file a registration statement and have it declared effective soon. The private placement is pending TSX Venture Exchange approval and aims to support gout treatment programs and general corporate purposes. On Monday, XRTX closed at $0.92.



Read more at Nasdaq.: XORTX Announces $3 Mln Private Placement To Advance Gout And Kidney Disease Program